News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Sarah Cannon Research Institute Sponsors Large-Scale Breast Cancer Trial
December 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NASHVILLE, Tenn.--(BUSINESS WIRE)--The Sarah Cannon Research Institute will enroll 1,800 breast cancer patients for its TITAN study, a clinical research trial investigating the role of ixabepilone (Ixempra) in the treatment of early breast cancer.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Immunology and inflammation
Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes
June 30, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Amgen’s Tavneos troubles continue as
NEJM
retracts pivotal publication
June 30, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit
June 29, 2026
·
2 min read
·
Tristan Manalac
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
·
2 min read
·
Tristan Manalac
